Natriuretic Peptides

The heart as an endocrine organ , a fact that still surprises people

Most of us grow up thinking about the heart as a pump. That's fair enough , it is. But somewhere around my second year of pharmacology, I hit a chapter on cardiac peptides and had a proper "wait, what?" moment. The heart secretes hormones. It monitors its own wall tension and responds by releasing signalling molecules into the bloodstream. That's not metaphor; it's straightforward endocrinology, and it's been known since the early 1980s.

Natriuretic peptides are those molecules. They're a family of structurally related peptides produced primarily , though not exclusively; by cardiac tissue, and they play a well-defined role in cardiovascular and renal physiology. This article covers what they are, how they're built, what the receptors do, and where the science genuinely stands. No performance framing. No anti-ageing angles. Just the biochemistry, and then the regulatory picture, because that matters here.

What natriuretic peptides actually are

The natriuretic peptide family has three main members in humans: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). A fourth, Dendroaspis natriuretic peptide (DNP), was originally isolated from the venom of the green mamba and is still a subject of ongoing research rather than a well-characterised human hormone.

ANP was the first identified, described by Adolfo de Bold and colleagues in 1981 after they demonstrated that injecting atrial tissue extracts into rats produced a rapid increase in urine and sodium excretion. "Natriuretic" literally means sodium-excreting, from the Latin natrium for sodium. BNP was subsequently isolated from porcine brain tissue in 1988 (hence the original "brain" label), though in humans it's produced predominantly by ventricular myocytes. CNP sits structurally apart from the other two and acts predominantly in vascular and bone tissue rather than the kidney.

Each of these molecules is built from amino acids connected by peptide bonds and shares a characteristic 17-amino-acid ring structure formed by a disulfide bridge between two cysteine residues. That ring is conserved across the family and appears essential for receptor binding. Outside the ring, the sequences diverge considerably, which is part of why different family members bind different receptors with different affinities.

Biosynthesis: from preprohormone to active peptide

ANP is synthesised as a 151-amino-acid preprohormone (preproANP) in atrial cardiomyocytes. After removal of a signal peptide, it becomes the 126-amino-acid proANP, which is stored in secretory granules. On release, triggered by atrial wall stretch, increased filling pressure, or various neurohormonal signals; it's cleaved by the membrane-bound serine protease corin into the active 28-amino-acid ANP and an N-terminal fragment.

BNP follows a slightly different route. It's synthesised as proBNP (108 amino acids) and is cleaved by corin and furin into active BNP-32 and the N-terminal fragment NT-proBNP. NT-proBNP has a much longer half-life than active BNP, roughly 60–120 minutes versus under 20 minutes, which is one reason it's become a useful clinical biomarker. The active molecule turns over quickly; the fragment sticks around longer and is easier to measure reliably.

This connects to broader pharmacokinetics: understanding how rapidly a peptide is cleared, and which metabolite you're measuring, matters enormously for interpreting any biological signal. Half-life in peptide science is rarely a simple number.

Receptors and second messengers

Three natriuretic peptide receptors have been characterised: NPR-A (also called NPR1 or GC-A), NPR-B (NPR2 or GC-B), and NPR-C (NPR3).

NPR-A is the primary receptor for ANP and BNP. It's a transmembrane receptor with an intracellular guanylyl cyclase domain; on ligand binding, it catalyses the conversion of GTP to cyclic GMP (cGMP). That cGMP signal then activates protein kinase G, which phosphorylates downstream targets involved in sodium excretion, vasodilation, and suppression of the renin-angiotensin-aldosterone axis.

NPR-B preferentially binds CNP and similarly signals through cGMP, but its tissue distribution is different; prominent in the central nervous system, bone, and vasculature rather than the kidney.

NPR-C is structurally distinct. It has only a short intracellular domain with no guanylyl cyclase activity, and its primary characterised role is as a clearance receptor: it binds natriuretic peptides and internalises them for lysosomal degradation. This is one of the main routes by which circulating peptide levels are regulated, alongside neutral endopeptidase (neprilysin) cleavage in the plasma and kidney.

Physiological roles: what the research shows

The core physiological picture from decades of research is reasonably consistent. ANP and BNP respond to increased cardiac wall stress, essentially, signals of volume overload or pressure overload, and act via cGMP signalling to promote sodium and water excretion by the kidney, relax vascular smooth muscle, and oppose the actions of vasoconstrictive and sodium-retaining systems like angiotensin II and aldosterone.

CNP's physiology is more local. In the vasculature it acts as an autocrine/paracrine signal rather than a classical circulating hormone. In endochondral bone formation, loss-of-function mutations in NPR-B in humans produce a skeletal dysplasia called acromesomelic dysplasia, type Maroteaux; which neatly demonstrates how much CNP-NPR-B signalling matters to normal bone growth, independent of the cardiovascular picture.

I'll be honest, the thing that got me genuinely interested in this family was not the cardiovascular physiology (which I'd read about plenty) but the bone biology angle. It's a good reminder that a peptide's name can be misleading about how broadly it acts.

For the curious, the signalling logic here has some structural parallels to how receptor-mediated cascades work in other biological systems, the concept of a ligand binding a specific receptor and triggering a defined second-messenger cascade appears across many molecular families, including the endocannabinoid system, where receptor specificity shapes tissue-level responses in comparably nuanced ways.

Synthetic analogues and the regulatory picture in Australia

Synthetic versions of natriuretic peptides have been developed and some have reached clinical use internationally. Nesiritide; a recombinant form of BNP, received approval in the United States in 2001. Carperitide (synthetic ANP) has been used in Japan. Both are parenteral products approved for specific acute clinical indications, administered under close medical supervision.

In Australia, the Therapeutic Goods Administration (TGA) is the regulator. Any peptide intended for therapeutic use must either be listed or registered on the Australian Register of Therapeutic Goods (the ARTG) or accessed through specific regulatory pathways: the Special Access Scheme or the Authorised Prescriber framework. Where a natriuretic peptide analogue is not approved on the ARTG, supplying it commercially in Australia, outside those approved pathways; is illegal under the Therapeutic Goods Act 1989.

The TGA has been increasingly active in enforcement against unapproved peptide products circulating through compounding pharmacies and online channels. A 2023 compliance campaign specifically targeted compounded peptide injectables, and the agency has made clear that the burden of proof for quality, safety, and efficacy rests with the sponsor or supplier, not with investigators post-hoc. This is worth stating plainly: peptides marketed online for physiological effects, outside any approved framework, exist in a legally and scientifically uncertain space. The TGA's published regulatory guidance on this is available at tga.gov.au.

Natriuretic peptides aren't typically the ones being peddled in that grey market, they're large, unstable molecules that require careful formulation and monitoring, and they're not the sort of thing anyone synthesises in a small-batch compounding context. But the regulatory framework is the same, and it's worth understanding.

Research directions: where the literature is going

The most active current research threads involve neprilysin inhibition (neutral endopeptidase inhibition to reduce natriuretic peptide degradation), designer CNP analogues for skeletal dysplasias, and the use of NT-proBNP as a prognostic biomarker. A 2021 review in Circulation Research summarised the translational state of the field well, noting that while the basic biology is established, therapeutic applications continue to require careful pharmacokinetic design, particularly around half-life extension strategies such as PEGylation and fusion protein approaches.

The bioavailability challenge is real. Natriuretic peptides are degraded rapidly in the gut and are not orally bioavailable, which is why clinical applications use intravenous or subcutaneous injection routes. Half-life engineering is an active area precisely because the endogenous molecules clear so quickly.

One direction I find genuinely interesting is the overlap between natriuretic peptide signalling and metabolic physiology; there's emerging research suggesting ANP and BNP may influence adipose tissue lipolysis via NPR-A/cGMP pathways. The GLP-1 receptor agonist class has reshaped how researchers think about peptide hormones in metabolic contexts, and the natriuretic peptide literature is picking up some of that energy. Early days, though. The short version is: interesting hypothesis, limited human data, worth watching.

Sources

• Natriuretic Peptides: Biochemistry, Physiology and Therapeutic Role, NCBI/PMC
• Regulatory guidance on compounded peptides, TGA (tga.gov.au)
• Natriuretic Peptides in Heart Failure; Circulation Research, AHA Journals
• Natriuretic Peptides, StatPearls, NCBI Bookshelf

, Priya Nandakumar, Pharmacology writer, peptides & PK